We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
Read MoreHide Full Article
Key Takeaways
HIMS reached 2.4 million subscribers in first-quarter 2025, up 38.4% year over year.
HIMS drove $576.4 million in online revenues, 115.3% higher than the prior year.
HIMS' deferred revenues hit $110.8 million, reflecting strength in prepaid services and future growth.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , has cemented its position as a leading direct-to-consumer healthcare platform by leveraging a subscription-based revenue model at the core of its operations. This model enables the company to provide continuous, personalized care while generating predictable, recurring revenue. As of the first quarter of 2025, Hims & Hers reported 2.4 million subscribers, a 38.4% year-over-year increase, with more than 1.4 million of them engaging in personalized solutions. This expansion directly contributed to $576.4 million in online revenue, representing 115.3% year-over-year growth, and forming nearly all of its $586 million in total revenues.
Hims & Hers’ focus on maximizing customer value is evident in the rise of its Monthly Online Revenue per Average Subscriber to $84, up 52.7% year over year from $55. This suggests not just subscriber growth, but deeper wallet share through upselling premium services, such as its newly launched GLP-1 weight loss offerings (e.g., Wegovy packages) and holistic wellness programs. Customers typically select from subscription cadences ranging from 30 to 360 days, offering both flexibility and continuity of care. With $110.8 million in deferred revenues as of March 2025, Hims & Hers has a robust pipeline of prepaid services yet to be delivered, underscoring the financial strength of this model.
Recent initiatives, including expanded GLP-1 access via partnerships with Novo Nordisk and NovoCare Pharmacy, further reinforce the value of the subscription model. By bundling medications, diagnostics, and 24/7 clinical support into recurring plans, Hims & Hers has not only addressed rising demand for weight management solutions but has also positioned itself to scale efficiently across new specialties. Subscriptions remain the company’s engine for long-term growth, operational leverage and customer loyalty.
Subscription-Led Growth Trajectories of LFMD & DOCS
LifeMD, Inc. (LFMD - Free Report) reported that 86% of its first-quarter 2025 revenues came from recurring subscription services. The company’s offerings span chronic care, weight management and telehealth services, mostly delivered through multi-month patient subscriptions. As of March 2025, LifeMD had 291,000 active subscribers, reflecting strong demand momentum. Its strategic bundling of services and robust telehealth infrastructure helped drive 70% year-over-year telehealth revenue growth, reinforcing LifeMD's high retention and recurring revenue efficiency.
Doximity, Inc. (DOCS - Free Report) relies on enterprise subscription contracts, generating the bulk of its revenue through its Marketing, Hiring and Workflow Solutions offered to healthcare systems and pharma clients. DOCS’ subscription revenues for fiscal 2025 constituted more than 95% of its total revenue base. These contracts are typically long-term, billed annually or quarterly, and recognized over time. Doximity reported a net revenue retention rate of 119%, underscoring the platform's ability to expand within its existing customer base and deepen recurring spend. A majority of Doximity’s revenues now stems from customers contributing over $500,000 annually, which demonstrates the depth and predictability of its enterprise-led model.
HIMS' Price Performance, Valuation and Estimates
Shares of Hims & Hers have surged 138.1% year to date compared with the industry’s gain of 29.7%.
Image Source: Zacks Investment Research
HIMS' forward 12-month P/S of 5X is lower than the industry’s average of 6.3X, but is higher than its five-year median of 2.6X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 170.4% improvement from 2024.
Image: Bigstock
HIMS' Subscriptions Power Personalized Care & Recurring Revenue Growth
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , has cemented its position as a leading direct-to-consumer healthcare platform by leveraging a subscription-based revenue model at the core of its operations. This model enables the company to provide continuous, personalized care while generating predictable, recurring revenue. As of the first quarter of 2025, Hims & Hers reported 2.4 million subscribers, a 38.4% year-over-year increase, with more than 1.4 million of them engaging in personalized solutions. This expansion directly contributed to $576.4 million in online revenue, representing 115.3% year-over-year growth, and forming nearly all of its $586 million in total revenues.
Hims & Hers’ focus on maximizing customer value is evident in the rise of its Monthly Online Revenue per Average Subscriber to $84, up 52.7% year over year from $55. This suggests not just subscriber growth, but deeper wallet share through upselling premium services, such as its newly launched GLP-1 weight loss offerings (e.g., Wegovy packages) and holistic wellness programs. Customers typically select from subscription cadences ranging from 30 to 360 days, offering both flexibility and continuity of care. With $110.8 million in deferred revenues as of March 2025, Hims & Hers has a robust pipeline of prepaid services yet to be delivered, underscoring the financial strength of this model.
Recent initiatives, including expanded GLP-1 access via partnerships with Novo Nordisk and NovoCare Pharmacy, further reinforce the value of the subscription model. By bundling medications, diagnostics, and 24/7 clinical support into recurring plans, Hims & Hers has not only addressed rising demand for weight management solutions but has also positioned itself to scale efficiently across new specialties. Subscriptions remain the company’s engine for long-term growth, operational leverage and customer loyalty.
Subscription-Led Growth Trajectories of LFMD & DOCS
LifeMD, Inc. (LFMD - Free Report) reported that 86% of its first-quarter 2025 revenues came from recurring subscription services. The company’s offerings span chronic care, weight management and telehealth services, mostly delivered through multi-month patient subscriptions. As of March 2025, LifeMD had 291,000 active subscribers, reflecting strong demand momentum. Its strategic bundling of services and robust telehealth infrastructure helped drive 70% year-over-year telehealth revenue growth, reinforcing LifeMD's high retention and recurring revenue efficiency.
Doximity, Inc. (DOCS - Free Report) relies on enterprise subscription contracts, generating the bulk of its revenue through its Marketing, Hiring and Workflow Solutions offered to healthcare systems and pharma clients. DOCS’ subscription revenues for fiscal 2025 constituted more than 95% of its total revenue base. These contracts are typically long-term, billed annually or quarterly, and recognized over time. Doximity reported a net revenue retention rate of 119%, underscoring the platform's ability to expand within its existing customer base and deepen recurring spend. A majority of Doximity’s revenues now stems from customers contributing over $500,000 annually, which demonstrates the depth and predictability of its enterprise-led model.
HIMS' Price Performance, Valuation and Estimates
Shares of Hims & Hers have surged 138.1% year to date compared with the industry’s gain of 29.7%.
Image Source: Zacks Investment Research
HIMS' forward 12-month P/S of 5X is lower than the industry’s average of 6.3X, but is higher than its five-year median of 2.6X. It carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 170.4% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.